Ketryx, a Cambridge, MA-based AI-powered compliance platform for life sciences and regulated industries, has raised $39 million in Series B funding, bringing its total funding to over $55 million.
Investors
The round was led by Transformation Capital, with participation from Lightspeed Venture Partners, MIT’s E14 Fund, Ubiquity Ventures, 53 Stations, and new investor Bill Hawkins (former Medtronic CEO).
Transformation Capital is a growth equity firm that invests exclusively in digital health and technology-enabled service companies. Based in Boston, Massachusetts, the firm partners with entrepreneurs to help them navigate the complexities of the healthcare industry.
Vinay Shah, Partner and Founding Team Member at Transformation Capital, will join Ketryx’s board.
Ketryx Use of Funds
The company will use the funds to expand globally, accelerate product development, and scale hiring across Boston and Austria.
About Ketryx
Founded by Erez Kaminski, Ketryx is an AI-native compliance platform helping life sciences and regulated industries release safer products faster. The platform automates validation, traceability, and regulatory workflows, including FDA- and EU MDR-ready documentation, to reduce documentation time. Headquartered in Cambridge, Massachusetts, its mission is to make systems safe and reliable. Ketryx serves three of the top five global medtech companies, Fortune 500 enterprises, and leading AI healthtech innovators such as DeepHealth, Heartflow, and Aignostics.
Funding Details
Company: Ketryx Corporation
Raised: $39.0M
Round: Series B
Funding Date: September 2025
Lead Investor: Transformation Capital
Additional Investors: Lightspeed Venture Partners, MIT’s E14 Fund, Ubiquity Ventures, 53 Stations, Bill Hawkins
Company Website: https://www.ketryx.com/
Software Category: Compliance Automation / Regulated AI Infrastructure
Source: https://www.ketryx.com/press-release/series-b